Trial Profile
Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 05 Feb 2024 Status changed from active, no longer recruiting to completed.
- 24 May 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 24 May 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.